z-logo
open-access-imgOpen Access
Enzymatic activity characterization of SARS coronavirus 3C‐like protease by fluorescence resonance energy transfer technique 1
Author(s) -
CHEN Shuai,
CHEN Lili,
LUO Haibin,
SUN Tao,
CHEN Jing,
YE Fei,
CAI Jianhua,
SHEN Jingkang,
SHEN Xu,
JIANG Hualiang
Publication year - 2005
Publication title -
acta pharmacologica sinica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.514
H-Index - 90
eISSN - 1745-7254
pISSN - 1671-4083
DOI - 10.1111/j.1745-7254.2005.00010.x
Subject(s) - protease , enzyme , förster resonance energy transfer , coronavirus , virology , covid-19 , severe acute respiratory syndrome coronavirus , chemistry , fluorescence , biochemistry , medicine , physics , pathology , quantum mechanics , infectious disease (medical specialty) , outbreak , disease
Aim: To characterize enzymatic activity of severe acute respiratory syndrome (SARS) coronavirus (CoV) 3C‐like protease (3CL pro ) and its four site‐directed mutants. Methods: Based on the fluorescence resonance energy transfer (FRET) principle using 5‐[(2′‐aminoethyl)‐amino] naphthelenesulfonic acid (EDANS) and 4‐[[4‐(dimethylamino) phenyl] azo] benzoic acid (Dabcyl) as the energy transfer pair, one fluorogenic substrate was designed for the evaluation of SARS‐CoV 3CL pro proteolytic activity. Results: The kinetic parameters of the fluorogenic substrate have been determined as K m =404 μmol·L ‐1 , k cat =1.08 min ‐1 , and k cat / K m =2.7 mmol ‐1 ·L·min ‐1 . SARS‐CoV 3CL pro showed substantial pH and temperature‐triggered activity switches, and site‐directed mutagenesis analysis of SARS‐CoV 3CL pro revealed that substitutions of His 41 , Cys 145 , and His 163 resulted in complete loss of enzymatic activity, while replacement of Met 162 with Ala caused strongly increased activity. Conclusion: This present work has provided valuable information for understanding the catalytic mechanism of SARS‐CoV 3CL pro . This FRET‐based assay might supply an ideal approach for the exploration SARS‐CoV 3CL pro putative inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here